TY - JOUR
T1 - PfMFR3
T2 - A Multidrug-Resistant Modulator in Plasmodium falciparum
AU - Rocamora, Frances
AU - Gupta, Purva
AU - Istvan, Eva S.
AU - Luth, Madeline R.
AU - Carpenter, Emma F.
AU - Kümpornsin, Krittikorn
AU - Sasaki, Erika
AU - Calla, Jaeson
AU - Mittal, Nimisha
AU - Carolino, Krypton
AU - Owen, Edward
AU - Llinás, Manuel
AU - Ottilie, Sabine
AU - Goldberg, Daniel E.
AU - Lee, Marcus C.S.
AU - Winzeler, Elizabeth A.
N1 - Funding Information:
This work was supported by the Bill and Melinda Gates Foundation (OPP1054480 - Target Discovery for Antimalarials). M.R.L. and K.C. are supported in part by a Ruth L. Kirschstein Institutional National Research Award from the National Institute for General Medical Sciences (T32 GM008666).
Publisher Copyright:
© 2021 Not subject to U.S. Copyright. Published by American Chemical Society.
PY - 2021/4/9
Y1 - 2021/4/9
N2 - In malaria, chemical genetics is a powerful method for assigning function to uncharacterized genes. MMV085203 and GNF-Pf-3600 are two structurally related napthoquinone phenotypic screening hits that kill both blood- and sexual-stage P. falciparum parasites in the low nanomolar to low micromolar range. In order to understand their mechanism of action, parasites from two different genetic backgrounds were exposed to sublethal concentrations of MMV085203 and GNF-Pf-3600 until resistance emerged. Whole genome sequencing revealed all 17 resistant clones acquired nonsynonymous mutations in the gene encoding the orphan apicomplexan transporter PF3D7_0312500 (pfmfr3) predicted to encode a member of the major facilitator superfamily (MFS). Disruption of pfmfr3 and testing against a panel of antimalarial compounds showed decreased sensitivity to MMV085203 and GNF-Pf-3600 as well as other compounds that have a mitochondrial mechanism of action. In contrast, mutations in pfmfr3 provided no protection against compounds that act in the food vacuole or the cytosol. A dihydroorotate dehydrogenase rescue assay using transgenic parasite lines, however, indicated a different mechanism of action for both MMV085203 and GNF-Pf-3600 than the direct inhibition of cytochrome bc1. Green fluorescent protein (GFP) tagging of PfMFR3 revealed that it localizes to the parasite mitochondrion. Our data are consistent with PfMFR3 playing roles in mitochondrial transport as well as drug resistance for clinically relevant antimalarials that target the mitochondria. Furthermore, given that pfmfr3 is naturally polymorphic, naturally occurring mutations may lead to differential sensitivity to clinically relevant compounds such as atovaquone.
AB - In malaria, chemical genetics is a powerful method for assigning function to uncharacterized genes. MMV085203 and GNF-Pf-3600 are two structurally related napthoquinone phenotypic screening hits that kill both blood- and sexual-stage P. falciparum parasites in the low nanomolar to low micromolar range. In order to understand their mechanism of action, parasites from two different genetic backgrounds were exposed to sublethal concentrations of MMV085203 and GNF-Pf-3600 until resistance emerged. Whole genome sequencing revealed all 17 resistant clones acquired nonsynonymous mutations in the gene encoding the orphan apicomplexan transporter PF3D7_0312500 (pfmfr3) predicted to encode a member of the major facilitator superfamily (MFS). Disruption of pfmfr3 and testing against a panel of antimalarial compounds showed decreased sensitivity to MMV085203 and GNF-Pf-3600 as well as other compounds that have a mitochondrial mechanism of action. In contrast, mutations in pfmfr3 provided no protection against compounds that act in the food vacuole or the cytosol. A dihydroorotate dehydrogenase rescue assay using transgenic parasite lines, however, indicated a different mechanism of action for both MMV085203 and GNF-Pf-3600 than the direct inhibition of cytochrome bc1. Green fluorescent protein (GFP) tagging of PfMFR3 revealed that it localizes to the parasite mitochondrion. Our data are consistent with PfMFR3 playing roles in mitochondrial transport as well as drug resistance for clinically relevant antimalarials that target the mitochondria. Furthermore, given that pfmfr3 is naturally polymorphic, naturally occurring mutations may lead to differential sensitivity to clinically relevant compounds such as atovaquone.
UR - http://www.scopus.com/inward/record.url?scp=85103777731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103777731&partnerID=8YFLogxK
U2 - 10.1021/acsinfecdis.0c00676
DO - 10.1021/acsinfecdis.0c00676
M3 - Article
C2 - 33715347
AN - SCOPUS:85103777731
SN - 2373-8227
VL - 7
SP - 811
EP - 825
JO - ACS Infectious Diseases
JF - ACS Infectious Diseases
IS - 4
ER -